Management of anticancer treatment in patients under chronic dialysis: Results of the multicentric CANDY (CANcer and DialYsis) study

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 501-507

  Janus, N ^a   Launay vacher, V ^a   Thyss, A ^b   Boulanger, H ^c   Moranne, O ^d   Islam, M S ^d   Durande, J P ^e   Ducret, M ^f   Juillard, L ^g   Soltani, Z ^h   Motte, G ^h   Rottembourg, J ⁱ   Deray, G ^a   Thariat, J ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c Clinique de l'Estrée   (France)

^d PASTEUR HOSPITAL   (France)

^e Hemodialysis center of Orgemont ^*  (France)

^f Centre Hospitalier de la Region d'Annecy   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h HÔPITAL DU BOCAGE   (France)

ⁱ Centre Suzanne Levy   (France)

Author keywords

Anticancer drug management; Chronic renal failure; Dialysability; Dialysis; Dosage adjustment; End stage renal disease

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY (TOPIC); PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY;

EID: 84873875042     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds344     Document Type: Article

References (36)

1. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99.
2. Vajdic CM, McDonald SP, McCredie MRE et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831.
3. Cuckovi C, Djukanovi L, Jankovi S et al. Malignant tumors in hemodialysis patients. Nephron 1996; 73: 710-712.
4. Matas AJ, Simmons RL, Kjellstrand CM et al. Increased incidence of malignancy during chronic renal failure. Lancet 1975; 1: 883-886.
5. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron 1977; 18: 182-184.
6. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33: 121-126.
7. Uchida K, Shoda J, Sugahara S et al. Comparison and survival of patients receiving hemodialysis and peritoneal dialysis in a single center. Adv Perit Dial 2007; 23: 144-149.
8. Lee JE, Han SH, Cho BC et al. Cancer in patients on chronic dialysis in Korea. J Korean Med Sci 2009; 24(suppl.): S95-S101.
9. Soares M, Salluh JIF, Carvalho MS et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol 2006; 24: 4003-4010.
10. Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol 2008; 21: 166-174.
11. Janus N, Launay-Vacher V, Karie S et al. Vaccination and chronic kidney disease. Nephrol Dial Transplant 2008; 23: 800-807.
12. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet 1992; 22: 434-446.
13. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-484.
14. Schupp N, Stopper H, Rutkowski P et al. Effect of different hemodialysis regimens on genomic damage in end-stage renal failure. Semin Nephrol 2006; 26: 28-32.
15. Schupp N, Heidland A, Stopper H. Genomic damage in endstage renal disease -contribution of uremic toxins. Toxins (Basel) 2010; 2: 2340-2358.
16. Aronoff G, Berns J, Brier M. Drug Prescribing in Renal Failure. Dosing Guidelines for Adults, 4th edition. American College of Physicians-American Society of Internal Medicine, Philadelphia 2004.
17. Launay-Vacher V, Karie S, Deray G. Guide de prescription des médicaments chez le patient insuffisant rénal, 4th edition. Paris: GPR Anticancéreux, Méditions International 2008.
18. Locatelli F, Becker H. Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of 'biosimilars'. Oncologist 2009; 14(Suppl. 1): 16-21.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
20. Wong G, Chapman JR. Cancers after renal transplantation. Transplant Rev (Orlando) 2008; 22: 141-149.
21. Tammemagi CM, Neslund-Dudas C, Simoff M et al. Impact of comorbidity on lung cancer survival. Int J Cancer 2003; 103: 792-802.
22. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30: 548-556.
23. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23: 253-262.
24. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
25. Boesler B, Czock D, Keller F et al. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 2005; 20: 1187-1191.
26. Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. Q J Med 1997; 90: 773-780.
27. Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2007; 2: 604-610.
28. Ciriaco P, Casiraghi M, Melloni G et al. Pulmonary resection for non-small-cell lung cancer in patients on hemodialysis: clinical outcome and long-term results. World J Surg 2005; 29: 1516-1519.
29. Tsuchida M, Yamato Y, Aoki T et al. Complications associated with pulmonary resection in lung cancer patients on dialysis. Ann Thorac Surg 2001; 71: 435-438.
30. Prestayko AW, D'Aoust JC, Issell BF et al. Cisplatin (cisdiamminedichloroplatinum II). Cancer Treat Rev 1979; 6: 17-39.
31. SiteGPR. http://www.sitegpr.com/ (28 April 2011, date last accessed).
32. Janus N, Launay-Vacher V, Deray G et al. Management of targeted therapies in hemodialysis patients. Bull Cancer 2011; http://www.ncbi.nlm.nih.gov/pubmed/22133789 (9 December 2011, date last accessed).
33. Janus N, Launay-Vacher V, Deray G et al. Management of chemotherapy in hemodialysis patients. Bull Cancer 2011; http://www.ncbi.nlm.nih.gov/pubmed/22133734 (9 December 2011, date last accessed).
34. Janus N, Thariat J, Boulanger H et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21: 1395-1403.
35. Li YF, Fu S, Hu W et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007; 17: 739-763.
36. Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 2009; 5: 450-462.